CATEGORY : Clinical Diagnostics

Life Science Market Reports

Our life science market intelligence products have been recognized by market insiders and outsiders alike for their accuracy, in-depth analysis, and unique insights.

Market Reports

Collaborative, Decentralized Research Drives Liquid Biopsy Advances – AGBT 2020

  For AGBT 2020, we analyzed collaboration networks within liquid biopsy publications to understand the landscape. We analyzed ~2,600 liquid biopsy publications 1, indexing ~1,300 affiliations and ~15,000 authors in 60

Digital Health Democratizes Precision Medicine to Improve Population Health

  By definition, precision medicine treats the individual while public health focuses on population-level interventions. While public health and precision medicine efforts overlap, some experts argue that precision medicine advancements

Select 2019 Trends and Discussions

  Los Angeles, CA January 3, 2019 – The end the last decade deepened my personal belief that the personalized medicine revolution will be driven by tools and diagnostics, rather

QIAGEN to Become Thermo?

In mid-November, speculation began that ThermoFisher was in talks with QIAGEN surrounding a potential acquisition. A hypothetical tie-up could help Thermo bolster its reach into clinical diagnostic tests and nucleic

Dx FTW

Los Angeles, CA November 26, 2019 – At DeciBio, we believe that the precision medicine revolution will be driven by improvements in life science research tools and diagnostics technologies! A

Pain Points, Unmet Needs, and Disruption in Precision Medicine – Part 1

DeciBio’s mission is to provide market intelligence and strategic insights that drive disruption and innovation in the precision medicine and life science industry. To this end, my colleague, Colin Enderlein,

An Updated Look at TMB: What Has Changed and What to Expect

Since we last reported on the rise of tumor mutational burden (TMB) in immuno-oncology (I/O) a year ago, there have been numerous material developments of this biomarker in the I/O

Pulse Survey: Adoption and Utilization of Next Generation Cancer Biomarkers

The way cancer is diagnosed, treated, and monitored is changing more rapidly than ever. In 2019, we expect there to be catalysts that fundamentally change cancer companion diagnostic biomarker testing (i.e.,

Guardant Health stock soars after IPO, Lexent Bio joins the serial monitoring gold rush and a UK research team develops a novel cfDNA assay

Want to keep up with the latest liquid biopsy market research developments? Take our 6 minute survey and sign up for our weekly newsletter. DeciBio Liquid Biopsy Weekly Digest September 27, 2018